利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

34 条记录 (耗时 0.036 秒)

    Remedy for chronic disease
    33.
    发明授权
    Remedy for chronic disease 失效
    缓解慢性病的治疗方法

    公开(公告)号：US07300917B2

    公开(公告)日：2007-11-27

    申请号：US10519106

    申请日：2003-05-28

    申请人： Shinji Nakade ,  Hiromu Habashita ,  Takuya Seko

    发明人： Shinji Nakade ,  Hiromu Habashita ,  Takuya Seko

    IPC分类号： A61K38/00 ,  C12P13/06

    CPC分类号： C07D213/40 ,  A61K31/4406 ,  C07C233/51 ,  C07C233/66 ,  C07C233/73 ,  C07C233/83 ,  C07C235/48 ,  C07C235/52 ,  C07D231/12 ,  C07D235/12 ,  C07D261/14

    摘要： A remedy and/or a preventive for a chronic disease which contains an EDG-2 antagonist. Because of binding to a subtype EDG-2 of LPA receptor, an EDG-2 antagonist is useful in treating and/or preventing chronic diseases (for example, diseases caused by the progress of chronic asthma, glomerular nephritis, obesity, arteriosclerosis, rheumatoid and atopic diseases) induced and made chronic by tissue cells whose proliferation is accelerated by LPA mediated by EDG-2.

    摘要翻译： 含有EDG-2拮抗剂的慢性疾病的补救措施和/或预防措施。 由于与EDA-2的LPA受体的结合，EDG-2拮抗剂可用于治疗和/或预防慢性疾病（例如由慢性哮喘，肾小球肾炎，肥胖症，动脉硬化，类风湿病， 特应性疾病）由EDG-2介导的LPA加速的组织细胞诱导和慢性。

    β-alanine derivatives and the use thereof
    34.
    发明授权
    β-alanine derivatives and the use thereof 失效
    β-丙氨酸衍生物及其用途

    公开(公告)号：US07285680B2

    公开(公告)日：2007-10-23

    申请号：US10515653

    申请日：2003-05-28

    申请人： Hiromu Habashita ,  Masahiko Terakado ,  Shinji Nakade ,  Takuya Seko

    发明人： Hiromu Habashita ,  Masahiko Terakado ,  Shinji Nakade ,  Takuya Seko

    IPC分类号： C07C233/83 ,  C07C311/46 ,  C07D209/16 ,  C07D213/40 ,  C07D217/06 ,  C07D307/52

    CPC分类号： C07D213/40 ,  C07C233/83 ,  C07C311/46 ,  C07C2602/08 ,  C07C2602/10 ,  C07D209/16 ,  C07D213/38 ,  C07D217/06 ,  C07D307/52 ,  C07D333/20 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12

    摘要： A compound of the general formula (I) (wherein the symbols are as defined in the description), or a prodrug or a salt thereof. This compound engages in LPA receptor bonding and antagonism and hence is useful in the prevention and/or treatment of urinary system disease (symptom with prostatic hypertrophy or neurogenic bladder dysfunction disease, symptom to be caused by spinal cord neoplasm, nucleous hernia, spinal canal stenosis or diabetes, lower urinary tract symptom (for example, occlusion disease of lower urinary tract), inflammatory disease of lower urinary tract, polyuria), carcinoma association disease (solid tumor, solid tumor metastasis, angiofibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leucemia and carcinomatous infiltration transition), proliferative disease (disorder with aberrant angiogenesis, artery obstruction and pulmonary fibrosis), inflammation/immune system disease (psoriasis, nephropathy, hepatitis and pneumonitis symptom), disease by secretion fault (Sjogren syndrome) or brain association disease (brain infarction, cerebral apoplexy and brain or peripheral neuropathy).

    摘要翻译： 通式（I）的化合物（其中符号如说明书中所定义）或其前药或其盐。 该化合物参与LPA受体结合和拮抗作用，因此可用于预防和/或治疗泌尿系统疾病（前列腺肥大或神经源性膀胱功能障碍症状，由脊髓肿瘤引起的症状，核疝，椎管狭窄 或糖尿病，下尿路症状（例如下泌尿道闭塞病），下尿路炎性多发尿，多尿症），癌相关疾病（实体瘤，实体瘤转移，血管纤维瘤，骨髓瘤，多发性骨髓瘤，卡波西肉瘤， 炎症/免疫系统疾病（牛皮癣，肾病，肝炎和肺炎症状），分泌性疾病（干燥综合症）或脑关联疾病 （脑梗死，脑中风和脑或周围神经病变）。